{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:04:21Z","timestamp":1790615061442,"version":"4.1.0"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/mnh.0b013e3283621510","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T08:59:48Z","timestamp":1370336388000},"page":"459-470","source":"Crossref","is-referenced-by-count":75,"title":["Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease"],"prefix":"10.1097","volume":"22","author":[{"given":"Olivier","family":"Devuyst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210205","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease.","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"R2-16-20210205","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years.","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"R3-16-20210205","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.bbadis.2011.01.011","article-title":"Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease.","volume":"1812","author":"Terryn","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"R4-16-20210205","first-page":"457","article-title":"Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: a histochemical study.","volume":"1","author":"Verani","year":"1988","journal-title":"Mod Pathol"},{"key":"R5-16-20210205","first-page":"F169","article-title":"Expression of aquaporins-1 and -2 during nephrogenesis and in autosomal dominant polycystic kidney disease.","volume":"271","author":"Devuyst","year":"1996","journal-title":"Am J Physiol"},{"key":"R6-16-20210205","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease.","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-16-20210205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R8-16-20210205","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1681\/ASN.2006010052","article-title":"PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice.","volume":"18","author":"Ahrabi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R9-16-20210205","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"R10-16-20210205","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"R11-16-20210205","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ki.1989.38","article-title":"The clinical utility of renal concentrating capacity in polycystic kidney disease.","volume":"35","author":"Gabow","year":"1989","journal-title":"Kidney Int"},{"key":"R12-16-20210205","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","article-title":"Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.","volume":"7","author":"Zittema","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-16-20210205","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ki.2012.225","article-title":"Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.","volume":"82","author":"Ho","year":"2012","journal-title":"Kidney Int"},{"key":"R14-16-20210205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ki.1988.2","article-title":"Renal functional changes in experimental cystic disease are tubular in origin.","volume":"33","author":"Carone","year":"1988","journal-title":"Kidney Int"},{"key":"R15-16-20210205","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4<309::AID-DVG14>3.0.CO;2-5","article-title":"Developmental expression or urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.","volume":"24","author":"Gattone","year":"1999","journal-title":"Develop Gen"},{"key":"R16-16-20210205","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/sj.ki.5002788","article-title":"Contribution of TRPV channels to osmosensory transduction, thirst, and vasopressin release.","volume":"73","author":"Sharif-Naeini","year":"2008","journal-title":"Kidney Int"},{"key":"R17-16-20210205","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1083\/jcb.200805124","article-title":"TRPP2 and TRPV4 form a polymodal sensory channel complex.","volume":"182","author":"Kottgen","year":"2008","journal-title":"J Cell Biol"},{"key":"R18-16-20210205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-8993(99)01975-7","article-title":"Neuropeptide families and their receptors: evolutionary perspectives.","volume":"848","author":"Hoyle","year":"1999","journal-title":"Brain Res"},{"key":"R19-16-20210205","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1749-6632.2008.03659.x","article-title":"Major genomic events and their consequences for vertebrate evolution and endocrinology.","volume":"1163","author":"Larhammar","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"R20-16-20210205","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.1226860","article-title":"Vasopressinoxytocin-related signaling regulates gustatory associative learning in C. elegans.","volume":"338","author":"Beets","year":"2012","journal-title":"Science"},{"key":"R21-16-20210205","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1073\/pnas.0409534102","article-title":"Different G protein-coupled receptor kinases govern G protein and -arrestin-mediated signaling of V2 vasopressin receptor.","volume":"102","author":"Ren","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R22-16-20210205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"key":"R23-16-20210205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.","volume":"6","author":"Meijer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R24-16-20210205","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1093\/ndt\/gfs070","article-title":"Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with Autosomal Dominant Polycystic Kidney Disease.","volume":"27","author":"Boertien","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R25-16-20210205","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R26-16-20210205","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0272-6386(97)90496-0","article-title":"Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease.","volume":"30","author":"Yamaguchi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"R27-16-20210205","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"R28-16-20210205","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1681\/ASN.2006020136","article-title":"Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease.","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R29-16-20210205","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/ki.2008.111","article-title":"A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5 end of Pkd1.","volume":"73","author":"Starremans","year":"2008","journal-title":"Kidney Int"},{"key":"R30-16-20210205","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1172\/JCI64313","article-title":"Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.","volume":"122","author":"Hopp","year":"2012","journal-title":"J Clin Invest"},{"key":"R31-16-20210205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2009.438","article-title":"Cyclic nucleotide signaling in polycystic kidney disease.","volume":"77","author":"Wang","year":"2010","journal-title":"Kidney Int"},{"key":"R32-16-20210205","doi-asserted-by":"crossref","first-page":"10679","DOI":"10.1073\/pnas.1016214108","article-title":"Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases.","volume":"108","author":"Choi","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R33-16-20210205","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/hep.24723","article-title":"Altered store operated calcium entry increases cyclic 3,5-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.","volume":"55","author":"Spirli","year":"2012","journal-title":"Hepatology"},{"key":"R34-16-20210205","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1006\/bbrc.1998.9514","article-title":"The polycystic kidney disease-1 protein, polycystin-1, binds and activates heterotrimeric G-proteins in vitro.","volume":"251","author":"Parnell","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"R35-16-20210205","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2006111218","article-title":"Identification of a forskolin-like molecule in human renal cysts.","volume":"18","author":"Putnam","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R36-16-20210205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11302-008-9102-6","article-title":"Purinergic signaling in the lumen of a normal nephron and in remodeled PKD encapsulated cysts.","volume":"4","author":"Hovater","year":"2008","journal-title":"Purinergic Signal"},{"key":"R37-16-20210205","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00109-010-0715-1","article-title":"Formation of cysts by principal-like MDCK cells depends on the synergy of cAMP- and ATP-mediated fluid secretion.","volume":"89","author":"Buchholz","year":"2011","journal-title":"J Mol Med"},{"key":"R38-16-20210205","first-page":"1B","article-title":"Absence of adenylyl cyclase 6 is markedly protective in polycystic kidney disease in mice.","volume":"23","author":"Kohan","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R39-16-20210205","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.1073\/pnas.93.19.10206","article-title":"Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells.","volume":"93","author":"Brill","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R40-16-20210205","doi-asserted-by":"crossref","first-page":"C389","DOI":"10.1152\/ajpcell.1996.270.1.C389","article-title":"A role for CFTR in human autosomal dominant polycystic kidney disease.","volume":"270","author":"Hanaoka","year":"1996","journal-title":"Am J Physiol"},{"key":"R41-16-20210205","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway.","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int"},{"key":"R42-16-20210205","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells.","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R43-16-20210205","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2007060665","article-title":"Src inhibition ameliorates polycystic kidney disease.","volume":"19","author":"Sweeney","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R44-16-20210205","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00109-012-0902-3","article-title":"Polycystin-1 regulates amphiregulin expression through CREB and AP1 signalling: implications in ADPKD cell proliferation.","volume":"90","author":"Aguiari","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"R45-16-20210205","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/MCB.01259-08","article-title":"Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1.","volume":"29","author":"Distefano","year":"2009","journal-title":"Mol Cell Biol"},{"key":"R46-16-20210205","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/hep.23511","article-title":"Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.","volume":"51","author":"Spirli","year":"2010","journal-title":"Hepatology"},{"key":"R47-16-20210205","doi-asserted-by":"crossref","first-page":"9356","DOI":"10.1128\/MCB.20.24.9356-9363.2000","article-title":"Cyclic AMP promotes neuronal survival by phosphorylation of GSK3beta.","volume":"20","author":"Li","year":"2000","journal-title":"Mol Cell Biol"},{"key":"R48-16-20210205","doi-asserted-by":"crossref","first-page":"9971","DOI":"10.1074\/jbc.M508778200","article-title":"Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase.","volume":"281","author":"Taurin","year":"2006","journal-title":"J Biol Chem"},{"key":"R49-16-20210205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ydbio.2012.01.014","article-title":"A protein kinase A and Wnt-dependent network regulating an intermediate stage in epithelial tubulogenesis during kidney development.","volume":"364","author":"Gallegos","year":"2012","journal-title":"Dev Biol"},{"key":"R50-16-20210205","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cub.2009.11.072","article-title":"Identification of signaling pathways regulating primary cilium length and flow-mediated adaptation.","volume":"20","author":"Besschetnova","year":"2010","journal-title":"Curr Biol"},{"key":"R51-16-20210205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccr.2010.06.018","article-title":"SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.","volume":"18","author":"Ahmed","year":"2010","journal-title":"Cancer Cell"},{"key":"R52-16-20210205","doi-asserted-by":"crossref","first-page":"35812","DOI":"10.1074\/jbc.M605288200","article-title":"Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase.","volume":"281","author":"Liu","year":"2006","journal-title":"J Biol Chem"},{"key":"R53-16-20210205","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.2011030277","article-title":"c-Met and NF-B-dependent overexpression of Wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease.","volume":"23","author":"Qin","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R54-16-20210205","doi-asserted-by":"crossref","first-page":"F1166","DOI":"10.1152\/ajprenal.00196.2007","article-title":"Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL.","volume":"293","author":"Mutig","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R55-16-20210205","doi-asserted-by":"crossref","first-page":"F351","DOI":"10.1152\/ajprenal.00049.2006","article-title":"Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct.","volume":"292","author":"Carmosino","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R56-16-20210205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1523-1755.1998.00990.x","article-title":"Regulation of cAMP production in initial and terminal inner medullary collecting ducts.","volume":"54","author":"Yasuda","year":"1998","journal-title":"Kidney Int"},{"key":"R57-16-20210205","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R58-16-20210205","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"R59-16-20210205","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R60-16-20210205","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat.","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R61-16-20210205","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease.","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R62-16-20210205","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.","volume":"301","author":"Reif","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"R63-16-20210205","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1523-1755.2005.00703.x","article-title":"Vasopressin antagonists in polycystic kidney disease.","volume":"68","author":"Torres","year":"2005","journal-title":"Kidney Int"},{"key":"R64-16-20210205","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years experience.","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R65-16-20210205","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int"},{"key":"R66-16-20210205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-9966-29-19","article-title":"Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.","volume":"29","author":"Appetecchia","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"R67-16-20210205","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3,5-cyclic monophosphate.","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"R69-16-20210205","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"key":"R70-16-20210205","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"R71-16-20210205","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R72-16-20210205","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R73-16-20210205","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R74-16-20210205","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide.","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R75-16-20210205","doi-asserted-by":"crossref","first-page":"F1089","DOI":"10.1152\/ajprenal.00242.2012","article-title":"Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.","volume":"303","author":"Wang","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"R76-16-20210205","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/pr.110.003517","article-title":"International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress.","volume":"63","author":"Woodward","year":"2011","journal-title":"Pharmacol Rev"},{"key":"R77-16-20210205","doi-asserted-by":"crossref","first-page":"F1622","DOI":"10.1152\/ajprenal.00036.2007","article-title":"EP2 receptor mediates PGE2-induced cystogenesis of human renal epithelial cells.","volume":"293","author":"Elberg","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R78-16-20210205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.prostaglandins.2012.03.005","article-title":"Prostaglandin E2 stimulates cystogenesis through EP4 receptor in IMCD-3 cells.","volume":"98","author":"Elberg","year":"2012","journal-title":"Prost Lipid Mediat"},{"key":"R79-16-20210205","doi-asserted-by":"crossref","first-page":"F1425","DOI":"10.1152\/ajprenal.00010.2012","article-title":"Prostaglandin E(2) mediates proliferation and chloride secretion in ADPKD cystic renal epithelia.","volume":"303","author":"Liu","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"R80-16-20210205","doi-asserted-by":"crossref","first-page":"F868","DOI":"10.1152\/ajprenal.00183.2005","article-title":"Urine concentrating defect in prostaglandin EP1-deficient mice.","volume":"292","author":"Kennedy","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R81-16-20210205","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bbadis.2009.03.001","article-title":"Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A(3) adenosine receptors in human renal cells: implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells.","volume":"1792","author":"Aguiari","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"R82-16-20210205","doi-asserted-by":"crossref","first-page":"F15","DOI":"10.1152\/ajprenal.00103.2006","article-title":"Antagonism of endogenous putative P2Y receptors reduces the growth of MDCK-derived cysts cultured in vitro.","volume":"292","author":"Turner","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R83-16-20210205","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1681\/ASN.2010070728","article-title":"Inhibition of the P2X7 receptor reduces cystogenesis in PKD.","volume":"22","author":"Chang","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R84-16-20210205","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A case for water in the treatment of polycystic kidney disease.","volume":"4","author":"Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R85-16-20210205","first-page":"S93","article-title":"Is there a cardiovascular rationale for the use of combined vasopressin V1aV2 receptor antagonists Am J M","volume":"119","author":"Goldsmith","year":"2006","journal-title":"ed"},{"key":"R86-16-20210205","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2215\/CJN.04180609","article-title":"A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.","volume":"5","author":"Barash","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R87-16-20210205","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2215\/CJN.03950510","article-title":"Water prescription in autosomal dominant polycystic kidney disease: a pilot study.","volume":"6","author":"Wang","year":"2011","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Current Opinion in Nephrology &amp; Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNH.0b013e3283621510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T18:05:59Z","timestamp":1645639559000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041552-201307000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mnh.0b013e3283621510","relation":{},"ISSN":["1062-4821"],"issn-type":[{"value":"1062-4821","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}